Darren McGuire, MD
Cardiovascular Disease · Dallas, TXNPI 1336106715
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $910,035 of the $1,190,560 with a category attached, or 76.4%. It is spread thinly across 39 manufacturers, the largest accounting for just 14.2%. Reporting peaked in 2019 at $321,302 and has fallen 72.1% since, to $89,727 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 532 payments — averaging $2237.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$169K
- Novo Nordisk AS$166K
- Eli Lilly$156K
- Boehringer Ingelheim International GmbH$86K
- Boehringer Ingelheim$62K
- Merck$55K
- plus $497K from 33 others
Across 112 payments — averaging $3301.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$147K
- Boehringer Ingelheim International GmbH$122K
- Pfizer$57K
- Eli Lilly$19K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- Akebia Therapeutics Inc$6K
- plus $9K from 3 others
What the payments were for
- Consulting fees$910,03576%
- Speaking & faculty fees$108,2029%
- Travel & lodging$163,32714%
- Food & beverage$8,9961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$163,450
- TRADJENTA$49,854
- SOTAGLIFLOZIN$37,045
- Victoza$31,363
- STEGLATRO$24,321
- SOLIQUA 100/33$17,922
- FARXIGA$15,621
- Heplisav-B$11,750
- Tryvio$8,254
- BRILINTA$7,875
- SHINGRIX$7,198
- EPANOVA$6,125
- MOUNJARO$5,564
- Non-Covered$4,375
- LEQVIO$3,600
- Kerendia$2,800
- XARELTO$2,000
- INVOKANA$1,000
- Sotalol Hydrochloride$600
- NEXLETOL$116
How this compares
$1,190,560 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Ambarish PandeyDallas$325K
- Eric PetersonDallas$187K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
- Subhash BanerjeeDallas$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.